Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185(HER2/neu) monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

Mark D. Pegram, Allen Lipton, Daniel F. Hayes, Barbara L. Weber, Jose M. Baselga, Debu Tripathy, Debbie Baly, Sharon A. Baughman, Tom Twaddell, John A. Glaspy, Dennis J. Slamon

Research output: Contribution to journalArticlepeer-review

935 Scopus citations

Abstract

Purpose: To determine the toxicity, pharmacokinetics, response rote, and response duration of intravenous (IV) administration of recombinant, humanized anti-p185(HER2) monadanal antibody (rhuMAb HER2) plus cisplatin (CDDP) in a phase II, open-label, multicenter clinical trial for patients with HER2/neu-overexpressing metastatic breast cancer. Patients and Methods: The study population consisted of extensively pretreated advanced breast cancer patients with HER2/neu overexpression and disease progression during standard chemotherapy. Patients received a loading dose of rhuMAb HER2 (250 mg IV) on day 0, followed by weekly doses of 100 mg IV for 9 weeks. Patients received CDDP (75 mg/m2) on days 1,29, and 57. Results: Of 37 patients assessable for response, nine (24.3%) achieved a PR, nine (24.3%) had a minor response or stable disease, and disease progression occurred in 19 (51.3%). The median response duration was 5.3 months (range, 1.6-18). Grade III or IV toxicity was observed in 22 of 39 patients (56%). The toxicity profile reflected that expected from CDDP alone with the most common taxicities being cytopenias (n = 10), nausea/vomiting (n = 9), and asthenia (n = 5). Mean pharmacokinetic parameters of rhuMAb HER2 were unaltered by coadministration of CDDP. Conclusion: The use of rhuMAb HER2 in combination with CDDP in patients with HER2/neu-overexpressing metastatic breast cancer results in objective clinical response rates higher than those reported previously for CDDP alone, or rhuMAb HER2 alone. In addition, the combination results in no apparent increase in toxicity. Finally, the pharmacology of rhuMAb HER2 was unaffected by coadministration with CDDP.

Original languageEnglish (US)
Pages (from-to)2659-2671
Number of pages13
JournalJournal of Clinical Oncology
Volume16
Issue number8
DOIs
StatePublished - Aug 1998

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185(HER2/neu) monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment'. Together they form a unique fingerprint.

Cite this